Ascentage Pharma Group International (36X.F)

2.1800 +0.0400 (+1.87%) As of 09:59AM CEST. Market open.

Ascentage Pharma Group International

Suzhou Industrial Park
68 Xinqing Road
Suzhou 215000
China
86 512 8555 7777
https://www.ascentage.cn

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 583

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Dajun Yang M.D., Ph.D.	Co-Founder, Chairman & CEO	615.99k	N/A	1963
Dr. Shaomeng Wang Ph.D.	Co-Founder, Chief Scientific Advisor & Non-Executive Director	150.1k	N/A	1965
Dr. Ming Guo	Co-Founder	N/A	N/A	1958
Mr. Thomas Knapp	Senior VP & General Counsel	N/A	N/A	1953
Dr. Yifan Zhai M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1963
Douglas Dong Fang	Senior Vice President of Preclinical Development	N/A	N/A	N/A
Jianfeng Wen	Senior Vice President of Pharmaceutical Science	N/A	N/A	N/A
Mr. Raymond Kmetz	Chief Business Officer	N/A	N/A	1958
Mr. Yifei Zhu	Chief Commercial Officer	N/A	N/A	1970
Mr. Cheung Ki Wong A.C.I.S., A.C.S., FCPA	Company Secretary	N/A	N/A	1983

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Corporate Governance

Ascentage Pharma Group International’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.